An activated plasma contact system is an abnormality observed in many Alzheimer’s disease (AD) patients. Since mild cognitive impairment (MCI) patients often develop AD, we analyzed the status of contact system activation in MCI patients. We found that kallikrein activity, high molecular weight kininogen cleavage, and bradykinin levels— measures of contact system activation— were significantly elevated in MCI patient plasma compared to plasma from age- and education-matched healthy individuals. Changes were more pronounced in MCI patients with impaired short-term recall memory, indicating the possible role of the contact system in early cognitive changes.
Cortes-CanteliM, MatteiL, RichardsAT, NorrisEH, StricklandS (2015) Fibrin deposited in the Alzheimer’s disease brain promotes neuronal degeneration. Neurobiol Aging36, 608–617.
8.
Cortes-CanteliM, PaulJ, NorrisEH, BronsteinR, AhnHJ, ZamolodchikovD, BhuvanendranS, FenzKM, StricklandS (2010) Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: A possible contributing factor to Alzheimer’s disease. Neuron66, 695–709.
9.
ZamolodchikovD, Berk-RauchHE, OrenDA, StorDS, SinghPK, KawasakiM, AsoK, StricklandS, AhnHJ (2016) Biochemical and structural analysis of the interaction between beta-amyloid and fibrinogen. Blood128, 1144–1151.
AhnHJ, GlickmanJF, PoonKL, ZamolodchikovD, Jno-CharlesOC, NorrisEH, StricklandS (2014) A novel Abeta-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer’s disease mice. J Exp Med211, 1049–1062.
14.
ZamolodchikovD, RenneT, StricklandS (2016) The Alzheimer’s disease peptide beta-amyloid promotes thrombin generation through activation of coagulation factor XII. J Thromb Haemost14, 995–1007.
15.
HofmanZ, de MaatS, HackCE, MaasC (2016) Bradykinin: Inflammatoryroduct of the coagulation system. Clin Rev Allergy Immunol51, 152–161.
16.
LongAT, KenneE, JungR, FuchsTA, RenneT (2016) Contact system revisited: An interface between inflammation, coagulation, and innate immunity. J Thromb Haemost14, 427–437.
17.
ShibayamaY, JosephK, NakazawaY, GhebreihiwetB, PeerschkeEI, KaplanAP (1999) Zinc-dependent activation of the plasma kinin-forming cascade by aggregated beta amyloid protein. Clin Immunol90, 89–99.
18.
MaasC, Govers-RiemslagJW, BoumaB, SchiksB, HazenbergBP, LokhorstHM, HammarstromP, ten CateH, de GrootPG, BoumaBN, GebbinkMF (2008) Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest118, 3208–3218.
19.
BergamaschiniL, ParnettiL, PareysonD, CanzianiS, CugnoM, AgostoniA (1998) Activation of the contact system in cerebrospinal fluid of patients with Alzheimer disease. Alzheimer Dis Assoc Disord12, 102–108.
20.
ChenZL, SinghP, WongJ, HornK, StricklandS, NorrisEH (2019) An antibody against HK blocks Alzheimer’s disease peptide beta-amyloid-induced bradykinin release in human plasma. Proc Natl Acad Sci U S A116, 22921–22923.
21.
Yamamoto-ImotoH, ZamolodchikovD, ChenZL, BourneSL, RizviS, SinghP, NorrisEH, Weis-GarciaF, StricklandS (2018) A novel detection method of cleaved plasma high-molecular-weight kininogen reveals its correlation with Alzheimer’s pathology and cognitive impairment. Alzheimers Dement (Amst)10, 480–489.
22.
ZamolodchikovD, ChenZL, ContiBA, RenneT, StricklandS (2015) Activation of the factor XII-driven contact system in Alzheimer’s disease patient and mouse model plasma. Proc Natl Acad Sci U S A112, 4068–4073.
23.
ChenZL, RevenkoAS, SinghP, MacLeodAR, NorrisEH, StricklandS (2017) Depletion of coagulation factor XII ameliorates brain pathology and cognitive impairment in Alzheimer disease mice. Blood129, 2547–2556.
24.
NestorPJ, ScheltensP, HodgesJR (2004) Advances in the early detection of Alzheimer’s disease. Nat Med10(Suppl), S34–41.
25.
FlickerC, FerrisSH, ReisbergB (1991) Mild cognitive impairment in the elderly: Predictors of dementia. Neurology41, 1006–1009.
26.
StorandtM, GrantEA, MillerJP, MorrisJC (2002) Rates of progression in mild cognitive impairment and early Alzheimer’s disease. Neurology59, 1034–1041.
ScheffSW, PriceDA, SchmittFA, DeKoskyST, MufsonEJ (2007) Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology68, 1501–1508.
29.
ChetelatG, DesgrangesB, de la SayetteV, ViaderF, BerkoukK, LandeauB, LaleveeC, Le DozeF, DupuyB, HannequinD, BaronJC, EustacheF (2003) Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment. Brain126, 1955–1967.
30.
JohnsonKA, JonesK, HolmanBL, BeckerJA, SpiersPA, SatlinA, AlbertMS (1998) Preclinical prediction of Alzheimer’s disease using SPECT. Neurology50, 1563–1571.
31.
De SantiS, de LeonMJ, RusinekH, ConvitA, TarshishCY, RocheA, TsuiWH, KandilE, BoppanaM, DaisleyK, WangGJ, SchlyerD, FowlerJ (2001) Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging22, 529–539.
32.
JagustWJ, EberlingJL, RichardsonBC, ReedBR, BakerMG, NordahlTE, BudingerTF (1993) The cortical topography of temporal lobe hypometabolism in early Alzheimer’s disease. Brain Res629, 189–198.
SongF, PoljakA, SmytheGA, SachdevP (2009) Plasma biomarkers for mild cognitive impairment and Alzheimer’s disease. Brain Res Rev61, 69–80.
35.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
36.
GrundmanM, PetersenRC, FerrisSH, ThomasRG, AisenPS, BennettDA, FosterNL, JackCRJr, GalaskoDR, DoodyR, KayeJ, SanoM, MohsR, GauthierS, KimHT, JinS, SchultzAN, SchaferK, MulnardR, van DyckCH, MintzerJ, ZamriniEY, Cahn-WeinerD, ThalLJ, Alzheimer’s Disease Cooperative S (2004) Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol61, 59–66.
37.
MoroneyJT, BagiellaE, DesmondDW, HachinskiVC, MolsaPK, GustafsonL, BrunA, FischerP, ErkinjunttiT, RosenW, PaikMC, TatemichiTK (1997) Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology49, 1096–1105.
38.
SinghPK, ChenZL, GhoshD, StricklandS, NorrisEH (2020) Increased plasma bradykinin level is associated with cognitive impairment in Alzheimer’s patients. Neurobiol Dis139, 104833.
39.
ScottCF, WenzelHR, TschescheHR, ColmanRW (1987) Kinetics of inhibition of human plasma kallikrein by a site-specific modified inhibitor Arg15-aprotinin: Evaluation using a microlate system and comparison with other proteases. Blood69, 1431–1436 .
40.
SmallBJ, ViitanenM, BackmanL (1997) Mini-Mental State Examination item scores as predictors of Alzheimer’s disease: Incidence data from the Kungsholmen Project, Stockholm. J Gerontol A Biol Sci Med Sci52, M299–M304.
41.
MuenchhoffJ, PoljakA, SongF, RafteryM, BrodatyH, DuncanM, McEvoyM, AttiaJ, SchofieldPW, SachdevPS (2015) Plasma protein profiling of mild cognitive impairment and Alzheimer’s disease across two independent cohorts. J Alzheimers Dis43, 1355–1373.
42.
AssiniA, CammarataS, VitaliA, ColucciM, GilibertoL, BorghiR, IngleseML, VolpeS, RattoS, Dagna-BricarelliF, BaldoC, ArgustiA, OdettiP, PicciniA, TabatonM (2004) Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology63, 828–831.
43.
EliasMF, BeiserA, WolfPA, AuR, WhiteRF, D’AgostinoRB (2000) The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort. Arch Neurol57, 808–813.
WangQ, WangJ (2002) Injection of bradykinin or cyclosporine A to hippocampus induces Alzheimer-like phosphorylation of Tau and abnormal behavior in rats. Chin Med J (Engl)115, 884–887.
46.
AbbottNJ (2000) Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol20, 131–147.
47.
MielkeMM, HaugheyNJ, BandaruVV, SchechS, CarrickR, CarlsonMC, MoriS, MillerMI, CeritogluC, BrownT, AlbertM, LyketsosCG (2010) Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement6, 378–385.
48.
LinCH, YangHT, ChiuCC, LaneHY (2017) Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging. Sci Rep7, 14849.
